Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2016

View Archived Issues

EILV as an affordable and efficient alphavirus vaccine platform against chikungunya fever

SAR-408701 shows acceptable safety profile in patients with solid tumors

ADCT-502 shows promise for low HER2-expressing solid cancers

Phase II results from the LUME-MESO trial of nintedanib in mesothelioma

Exosomal miRNAs show potential as rapid and noninvasive biomarkers of NSCLC

Facio identifies variety of compounds with ability to repress production of DUX4 protein

Prima BioMed announces interim data from first-in-human combination phase I study of IMP-321

FDA issues complete response letter regarding Cempra's NDAs for solithromycin

Bavarian Nordic commences study of CV-301 plus nivolumab in NSCLC

Pivotal study of BioCardia's CardiAMP in heart failure begins

Phase II results for F-17464 in patients with acutely exacerbated schizophrenia

Medical Prognosis Institute and Oncology Venture sign series of agreements

FDA issues refusal to file letter for Innocoll's Xaracoll

Intarcia enters relationship with Bill & Melinda Gates Foundation for HIV prophylactic therapy

FDA grants orphan drug designation to MacroGenics' CD123 x CD3 DART protein for AML

U.S. orphan drug designation for ganaxolone in fragile X syndrome

FDA awards orphan drug designation to Yisheng's rabies vaccine

Keytruda granted U.S. orphan drug designation for Merkel cell carcinoma

East China University of Science and Technology patents HER1 inhibitors

Femtogenix discloses anticancer agents

FDA grants orphan drug designation to silmitasertib for cholangiocarcinoma

Hangzhou Innogate Pharma describes SYK/HDAC inhibitors

Basilea Pharmaceutica develops antibacterial activity enhancers

TetraLogic completes sale of two programs to Medivir

Merck & Co. presents adenosine A2A receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...